ADMA Biologics ADMA Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost.
The official record: ADMA Biologics’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →
Ask your AI about ADMA Biologics's deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ADMA Biologics's deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost?
- ADMA Biologics (ADMA) reported deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost of $3.92M in Q4 2025.